Comparative effective dose of ciprofol and propofol in suppressing cardiovascular responses to tracheal intubation
Authors:
Open Access
- 13 January 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Abstract
Ciprofol, a novel γ-aminobutyric acid receptor agonist, outperforms propofol with minimal cardiovascular effects, higher potency, reduced injection pain, and a broader safety margin. Despite these advantages, ciprofol’s clinical research is still emerging. This study compares the median effective dose (ED50) and adverse reactions of ciprofol and propofol, in conjunction with sufentanil, for suppressing cardiovascular responses during tracheal intubation. Fifty-three adult patients scheduled for tracheal intubation under general anesthesia were enrolled and randomly assigned to receive either ciprofol (Group C) or propofol (Group P), according to a random number table. Tracheal intubation was performed using a standardized laryngoscope and endotracheal tube. The Dixon’s up-and-down method was employed to determine the ED50 and 95% effective dose (ED95) of ciprofol and propofol in inhibiting cardiovascular responses during tracheal intubation. Based on the pilot study, the initial dose for ciprofol was set at 0.35 mg/kg (with a 0.01 mg/kg increment) and for propofol at 2.0 mg/kg (with a 0.1 mg/kg increment). Probit analysis was applied to derive dose-response curves, while adverse reactions were continuously monitored. A total of 54 participants were included, with 24 in group C (1 excluded) and 30 in group P. Probit analysis revealed that the ED50 of ciprofol for inhibiting cardiovascular responses to tracheal intubation were 0.326 mg/kg (95% CI 0.304–0.337 mg/kg), and for propofol, 1.541 mg/kg (95% CI 1.481–1.599 mg/kg). The heart rate in group P was significantly higher than the group C at 1 minute (p = 0.026) and 3 minutes (p = 0.016) post-intubation. Systolic and diastolic blood pressures (SBP and DBP) decreased significantly before and after intubation compared to baseline values in both groups (p< 0.05). Group C experienced significantly less injection pain (p = 0.001), although the incidence of other adverse effects was not statistically different between groups (p > 0.05). Clinical Trial Registration: hppts://ClinicalTrials.gov; Identifier: NCT06095570(18/10/2023).Keywords
All Related Versions
Funding Information
- Hainan Province Clinical Medical Center.
This publication has 46 references indexed in Scilit:
- Gender Affects the Median Effective Dose and 95% Effective Dose of Oxycodone for Blunting the Hemodynamic Response to Tracheal Intubation in Narcotic-Naïve Adult PatientsChinese Medical Journal, 2018
- Guidelines for the management of tracheal intubation in critically ill adultsBritish Journal of Anaesthesia, 2018
- Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General AnestheticsJournal of Medicinal Chemistry, 2017
- Pharmacological Agents for Reducing the Haemodynamic Response to Tracheal Intubation in Paediatric Patients: A Systematic ReviewAnaesthesia and Intensive Care, 2016
- The effect of additional propofol on intubation conditionsJournal of Clinical Anesthesia, 2010
- Dose-dependent hemodynamic effects of propofol induction following brotizolam premedication in hypertensive patients taking angiotensin-converting enzyme inhibitorsJournal of Clinical Anesthesia, 2010
- Different small-dose sufentanil blunting cardiovascular responses to laryngoscopy and intubation in children: a randomized, double-blind comparisonBritish Journal of Anaesthesia, 2008
- Evaluation of the cardiovascular responses to fiberoptic orotracheal intubation with television monitoring: comparison with conventional direct laryngoscopyJournal of Clinical Anesthesia, 2000
- Pharmacokinetics of sufentanil in normal childrenCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1992
- Staircase bioassay: The up-and-down methodNeuroscience & Biobehavioral Reviews, 1991